Please provide your email address to receive an email when new articles are posted on . SAN FRANCISCO — A study showed Bimatoprost sustained-release implant was noninferior to timolol and may ...

IRVINE, Calif. - Allergan today announced that the U.S. Food and Drug Administration has approved COMBIGAN™ (brimonidine tartrate/timolol maleate ophthalmic ...

Laser treatment has the potential to transform the management of glaucoma in Africa, and to prevent more people from going irreversibly blind, particularly in regions with high disease prevalence and ...

We read this paper with interest. The study is an economic evaluation of topical antagonists and prostaglandin analogues for the treatment of glaucoma. It uses a Markov model to explore costs, and ...

Feb. 11, 2004 -- Latanoprost was more effective than timolol at lowering intraocular pressure (IOP), according to the results of a randomized crossover study published in the February issue of the ...

Glaucoma is one of the three leading causes of blindness in Germany and worldwide. This neurodegenerative disease progressively damages the retinal nerve fibres, leading to irreversible vision loss.

Researchers at the University of Toronto see a future where a single injection under the eyelid could replace months of daily eye drops to treat glaucoma, a leading cause of blindness. A team led by ...

The FDA approved the travoprost intracameral implant (iDose TR) for treatment of ocular hypertension and glaucoma, device developer Glaukos announced on Thursday. The implant is designed to provide ...

A broad review of therapeutic classes approved for the management of glaucoma and how they may be sequenced. Neil Minkoff, MD: And just to help make sure that we’re all at least on a level playing ...